EX-99.1 2 bsem-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 BioStem Technologies Reports Second Quarter 2026 Financial Results Generates 29% sequential revenue growth, increasing to $7.9 million; Raises full-year 2026 revenue guidance Uplists to Nasdaq Capital Market POMPANO BEACH, FL, August 12, 2026 (GLOBE NEWSWIRE) - BioStem Technologies, Inc. (Nasdaq: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today reported financial results for the second quarter ended June 30, 2026. Recent Corporate Highlights • Completed the uplisting of the Company’s common stock to the Nasdaq Capital Market on August 7, 2026 • Completed a $2.5 million private placement with the Company’s first institutional investor Recent Business Highlights • Generated net revenue of $7.9 million for the second quarter of 2026, representing sequential growth of 29% from $6.1 million in the first quarter of 2026 • Continued to scale the commercial organization, expanding the direct sales force, integrating the CRM and ERP systems, and transitioning all major group purchasing organization (GPO) agreement…
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
BioStem Technologies, Inc.
BSEMNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 12, 2026, BioStem Technologies, Inc. (the "Company") issued a press release announcing its financial results for the three and six months ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.…
Company context
Current securities
Historical securities (1)
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On August 12, 2026, BioStem Technologies, Inc. (the "Company") issued a press release announcing its financial results for the three and six months ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
Information in Exhibit 99.1 of this Form 8-K shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise incorporated by reference into any filing pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.